Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores.
Yan HuangLichang ChenRui HuangChuanwu ZhuJia ShangYunsong QianJianqi LianLonggen LiuJianning JiangChenghai LiuHonglian GuiQing XiePublished in: Therapeutic advances in chronic disease (2022)
Among patients with an mPAGE-B score ⩾9, TDF is associated with a lower HCC incidence than ETV in patients with CHB-related compensated cirrhosis.